Abstract:Introduction: Alzheimer's disease (AD) is characterized by the misfolding and aggregation of two major proteins: amyloid-beta (Aβ) and tau. Antibody-based PET radioligands are desirable due to their high specificity and affinity; however, antibody uptake in the brain is limited by the blood-brain barrier (BBB). Previously, we demonstrated that antibody transport across the BBB can be facilitated through interaction with the transferrin receptor (TfR), and the bispecific antibody-based PET ligands were capable of detecting Aβ aggregates via ex vivo imaging. Since tau accumulation in the brain is more closely correlated with neuronal death and cognition, we report here our strategies to prepare four F-18-labeled specifically engineered bispecific antibody probes for the selective detection of tau and Aβ aggregates to evaluate their feasibility and specificity, particularly for in vivo PET imaging. Methods: We first created and evaluated (via both in vitro and ex vivo studies) four specifically engineered bispecific antibodies, by fusion of single-chain variable fragments (scFv) of a TfR antibody with either a full-size IgG antibody of Aβ or tau or with their respective scFv. Using [18F]SFB as the prosthetic group, all four 18F-labeled bispecific antibody probes were then prepared by conjugation of antibody and [18F]SFB in acetonitrile/0.1 M borate buffer solution (final pH ~ 8.5) with an incubation of 20 min at room temperature, followed by purification on a PD MiniTrap G-25 size exclusion gravity column. Results: Based on both in vitro and ex vivo evaluation, the bispecific antibodies displayed much higher brain concentrations than the unmodified antibody, supporting our subsequent F18-radiolabeling. [18F]SFB was produced in high yields in 60 min (decay-corrected radiochemical yield (RCY) 46.7 ± 5.4) with radiochemical purities of >95%, confirmed by analytical high performance liquid chromatography (HPLC) and radio-TLC. Conjugation of [18F]SFB and bispecific antibodies showed a 65%-83% conversion efficiency with radiochemical purities of 95%-99% by radio-TLC. Conclusions: We successfully labeled four novel and specifically engineered bispecific antibodies with [18F]SFB under mild conditions with a high RCY and purities. This study provides strategies to create brain-penetrable F-18 radiolabeled antibody probes for the selective detection of tau and Aβ aggregates in the brain of transgenic AD mice via in vivo PET imaging.

Development of A Novel Radioiodinated Compound for Amyloid and Tau Deposition Imaging in Alzheimer's Disease and Tauopathy Mouse Models

In vivo evaluation of novel near-infrared fluorescence probe THK565 for imaging amyloid β and tau protein deposits in Alzheimer‘s mouse models

Preclinical and Clinical Study on [18F]DRKXH1: a Novel Β-Amyloid PET Tracer for Alzheimer’s Disease

Synthesis and Preclinical Evaluation of Diarylamine Derivative As Tau-PET Radiotracer for Alzheimer’s Disease

Synthesis and preclinical evaluation of diarylamine derivative as Tau-PET radiotracer for Alzheimer's Disease

Rational design synthesis and evaluation of a novel near-infrared fluorescent probe for selective imaging of amyloid-β aggregates in Alzheimer's disease

A Near-infrared Fluorescence and Positron Emission Tomography Bimodal Probe for in Vivo Imaging of Amyloid-β Species.

Molecular Imaging of Alzheimer's Disease-Related Sigma-1 Receptor in the Brain via a Novel Ru-Mediated Aromatic 18F-deoxyfluorination Probe

Amyloid Plaque Imaging with a Targeted MRI Contrast Agent in a Transgenic Mouse Model of Alzheimer’s Disease

Development of brain-penetrable antibody radioligands for in vivo PET imaging of amyloid-β and tau

High-fidelity imaging of amyloid-beta deposits with an ultrasensitive fluorescent probe facilitates the early diagnosis and treatment of Alzheimer's Disease

Biological Characteristics of [ 18 F]-THK523 for Tau Imaging

Imaging of Tau Pathology in a Tauopathy Mouse Model and in Alzheimer Patients Compared to Normal Controls

Near-Infrared Aggregation-Induced Emission Luminogens for In Vivo Theranostics of Alzheimer's Disease.

Radioiodinated Benzimidazole Derivatives As Single Photon Emission Computed Tomography Probes for Imaging of Β-Amyloid Plaques in Alzheimer's Disease

Smart Near-Infrared Fluorescence Probes with Donor–Acceptor Structure for in Vivo Detection of Β-Amyloid Deposits

Study Of Tau Deposition In Patients Of Alzheimer'S Disease With [F-18]-Apn-1607 Pet Tracer And Its Relationship With Cerebral Glucose Metabolism

Novel 18F-Labeled Benzoxazole Derivatives As Potential Positron Emission Tomography Probes for Imaging of Cerebral Β-Amyloid Plaques in Alzheimer’s Disease

Novel 18F-Labeled Benzofuran Derivatives with Improved Properties for Positron Emission Tomography (PET) Imaging of Β-Amyloid Plaques in Alzheimer’s Brains

Synthesis and evaluation of novel benzothiazole derivatives based on the bithiophene structure as potential radiotracers for β-amyloid plaques in Alzheimer’s disease

Preparation and Biological Evaluation of Re/99 Tcm (CO) 3 +-diphenyldiazene Derivative as Candidates for Imaging Aβ Plaques in the Brain